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Investigative Study into Huntington's Disease: Development,




Huntington’s disease is a neurological disorder characterized by rapid motor, cognitive, and
physical deterioration. At the cellular level, the mutated form of huntingtin induces neuronal
dysfunction and toxic protein aggregation through several mechanisms, which culminates in
rapid neurodegeneration. There have been significant advances in recent years in understanding
how the disease develops and progresses in the brain. There have been observable improvements
concerning therapeutic strategies and clinical trials for possible treatments; however, the current
strategies are subject to critical faults. Recently, researchers have begun to consider experimental
strategies that are designed to target the mechanisms that contribute to mutant huntingtin
overexpression, like transcription regulation, gene expression repression, and oxidative stress
inhibition. While these strategies show promising results, they will need to be thoroughly studied
to understand their practical applications. Furthermore, the ethics of these strategies need to be
discussed to address any lingering controversies. This literature review will aim to thoroughly
investigate the pathology behind Huntington’s disease and current/experimental therapeutic
strategies designed to treat the neurodegenerative disorder. An analysis of available articles
yielded an abundance of information concerning the development, presentation, therapeutic
treatment, and ethical considerations of Huntington’s disease.
Keywords: neurodegeneration, neurodegenerative disorder, Huntington’s disease, huntingtin, protein aggregation,
neuron, gene therapy, CRISPR
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Introduction
Huntington’s disease (HD) is a neurodegenerative disorder that appears to operate under a
genetic pattern of inheritance. Though the disorder did appear in literature in the 1840s, it was
not until the 1870s that the disorder was thoroughly observed and investigated by George
Huntington, from whom the disease earned its name. Huntington’s disease appears to result from
the extension of a CAG trinucleotide repeat in the gene encoding for the huntingtin in the human
genome. Normally, there are around 35 CAG trinucleotide repeats, but those affected by
Huntington’s often have more than 36 repeats. It is the mutated version of this gene that induces
the neurodegeneration associated with Huntington’s. The disease can be characterized by rapid
motor, cognitive, and physical deterioration. This deterioration culminates in an early fatality.
Even though it has been nearly two centuries since the disease was first recorded in literature,
there is still no treatment to reverse or slow the progression of disease. Current treatments can
only endeavor to alleviate any symptoms that may arise as a result of the disease. With the
continued advancement of technology and the establishment of novel therapeutic approaches,
researchers should consider novel techniques that can prevent the mutant huntingtin protein from
encouraging neuronal deterioration.
What is Neurodegenerative Disease?
The classification of neurological disorders as neurodegenerative diseases remains a
heavily debated topic, even to this day. The etymological breakdown of the word
neurodegeneration includes the prefix “neuro-” which refers to neuronal cells, and
“degeneration,” which refers to the process of losing structure/function (Przedborski et al, 2003).
By basic definition, the word neurodegeneration should refer to any pathological condition that
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primarily affects the function of neuronal cells. In practice, however, neurodegeneration can
disturb not only the function of neurons but also the surrounding cellular pathways. Neurologists
agree that, overall, neurodegenerative diseases should be classified as the progressive
deterioration of neuronal cells. Because some neurodegenerative diseases have similar origins,
neurologists have opted to diagnose through the clinical presentation of symptoms. Though there
are hundreds of different neurodegenerative disorders identified over the centuries, the most
prevalent disorders studied by neurologists are Alzheimer’s disease (AD), Parkinson’s disease
(PD), and Huntington’s disease (HD). This paper will focus primarily on the etiology and
pathogenesis of Huntington’s, and what current and experimental therapies exist for this
neurodegenerative disorder.
The pathway leading to neurodegeneration depends on a variety of factors related to
aging; however, the specific molecular mechanisms leading to the emergence of
neurodegeneration are not fully understood by neurologists. One of the most enduring debates
surrounding the etiology of neurodegenerative disorders concerns which factor majorly
influences neurodegenerative development. Some neurodegenerative disorders have been
observed to pass from generation to generation, suggesting that there must be an inherent genetic
basis. In these cases, the disease often appears as an autosomal dominant trait, as in
Huntington’s. However, the disease has been observed to appear as an autosomal recessive,
X-linked, or even a maternally-expressed trait. On the other hand, neurodegenerative disorders
have appeared spontaneously, leading neurologists to suggest that environmental or endogenic
factors may contribute to the emergence of the disease (Przedborski et al, 2003). There is no
clear answer as to which factor influences neurodegenerative development, so neurologists have
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postulated that genetic and environmental factors have the capacity to accelerate neuronal
degeneration.
During the normal aging process, neurons experience increased amounts of oxidative
stress, protein aggregation, and incidence of apoptosis. As previously mentioned, these neuronal
changes during normal aging are worsened by genetic, environmental, and endogenic factors. In
the later stages of life, progressive oxidative stress can induce cellular and neuronal damage,
which cannot be reversible to the rapid decline of cell production. As cell production decreases
with age, neurons tend to accumulate masses of damaged proteins which form aggregates within
cellular pathways. These aggregates can spread easily in the brains of elderly individuals,
contributing to accelerated neuronal dysfunction and apoptosis (Mattson and Magnus, 2006).
These aggregates, in conjunction with external influences, induce observable symptoms in
afflicted individuals, like cognitive decline, memory loss, and varying behavioral changes.
The observation that normal aging correlates with increased incidence of cellular stress
and apoptosis, in conjunction with the finding that the most common neurodegenerative diseases
have been observed predominantly in elderly individuals, indicates that the risk of
neurodegenerative development increases with age. Interestingly, Huntington’s is one of the few
neurodegenerative disorders that does not present predominantly in elderly individuals. It has
been observed that symptoms begin to manifest in middle-aged individuals with the age on onset
decreasing in subsequent generations, thus contrasting the theory that the elderly are most at risk
for neurodegenerative development (Jimenez-Sanchez et al, 2017).
History of Huntington’s Disease
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Suspected cases of Huntington’s disease can be traced back to as early as the Middle
Ages; however, it was not until the nineteenth century that the disease began to appear in
medicinal literature. Literature concerning this neurological disorder referred to it as  “choera,”
for the jerky, involuntary movements associated with the disorder (Bhattacharyya, 2016).
Though the disorder would appear more frequently in the 1840s, it was not until the 1870s that
the disorder was thoroughly observed and investigated by George Huntington. Huntington was
born into a family of physicians and grew up with daily exposure to a plentiful amount of
disease. When he eventually completed his medical training and began practicing, he noticed that
there were instances of neurological dysfunction present in several generations of families that
seemed to follow the pattern of autosomal dominant inheritance. By 1872, Huntington had
released the first investigative report into “choera” and detailed the symptoms and methods of
transmission associated with the disorder (Bhattacharyya, 2016). It was his logical presentation
of his findings that brought the disease international attention, with researchers calling it
“Huntington’s disease”. By the end of the nineteenth century, there was a spike in international
interest regarding the etiology, pathology, and iamatology of the disease.
Several biologists over the next few decades would further cement the autosomal
dominance theory of inheritance for Huntington’s through investigations of the pedigrees of
afflicted individuals. By the early twentieth century, the first study concerning the etiology of
Huntington’s was commissioned in the United States by Charles Davenport. He went on to
publish his findings that expanded upon the age range when symptoms would manifest and the
kinds of symptoms afflicted individuals could experience (Davenport and Muncey, 1916). He
publicized the idea that many cases of Huntington’s in the United States could be traced back to
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several founding families. By 1968, this disorder was further popularized when the Hereditary
Disease Foundation was founded to conduct research on the causes and treatments for genetic
neurological conditions (Hereditary Disease Foundation, 2021). By 1983, there was a
breakthrough by the US-Venezuela Huntington's Disease Collaborative Project. Over ten years,
they had analyzed populations in South America with high rates of disease expression. Through
genetic linkage analysis and DNA-marker visualization, they were able to determine that the
gene responsible for the disease was located at human chromosome 4 (MacDonald, 1993). Later
that decade, experiments with transgenic mice would reveal that the disease manifested with the
presence of misfolded fragments associated with the gene, which would be called the huntingtin
protein (MacDonald, 1993). Advances in the past few decades have provided opportunities for
more extensive research concerning potential drug treatments, genetic therapies, and the protein
itself.
Huntingtin to Huntington’s Disease
Neuronal deterioration is associated with the accumulation of misfolded proteins, either
in the form of aggregated mutations, prions, -amyloid, or tau. In Huntington’s disease,
mutations in the HTT gene cause -amyloid growths that induce neurodegeneration. Encoded
from HTT, the huntingtin protein measures approximately 350kDa with a polyglutamine
sequence and consensus sequences important for regulating protein-protein interactions.
Huntingtin is widely expressed throughout but can be found most predominantly in cells
belonging to the central nervous system. Normal levels of huntingtin can influence embryonic
development, transcription regulation, and synaptic connectivity. The polyglutamine tract located
in the HTT gene plays an important part in regulating many of these cellular pathways.
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Normally, the tract contains around 35 CAG trinucleotide repeats, whereas those affected by
Huntington’s often have more than 36 repeats (Jimenez-Sanchez et al, 2017). It is the mutated
version of this gene that induces the aggregates and cellular interference responsible for
Huntington’s.
Mutations of huntingtin can cause protein aggregation via nucleated growth
polymerization, leading the polyglutamine tract to convert into -sheets held together by
hydrogen bonds in an amyloid structure. Neurologists have determined that these aggregates are
not necessarily always deleterious in terms of function, but cannot agree on the intrinsic nature of
the aggregates. Some studies have shown that aggregates of the polyglutamine tract have been
found in increased quantities in individuals afflicted by accelerated neurodegeneration,
suggesting that there is a direct link between aggregation and cell death (Hackam et al, 1998).
On the other hand, some studies have shown an inverse correlation between aggregation and cell
death, suggesting that the increased presence of aggregates may serve a supportive role by
protecting the neuronal cells from toxic exposure (Arrasate et al, 2004). The consensus, however,
by those studying neurodegeneration in Huntington’s is that these -amyloid growths disrupt the
daily functioning of neurons, thus accelerating the rate of neurodegeneration.
Mutation of the huntingtin protein does not only induce simple protein aggregation, but
toxic fragmentation, transcription interference, and gene expression alterations. When huntingtin
is mutated, the protein often experiences  impromptu fragmentation. These mutant fragments tend
to adopt toxic characteristics, due to their tendency to form nuclear aggregates (Hackam et al,
1998). Mutant huntingtin has been known to interfere with cellular transcription, as well.
Because activation domains in several transcription factors tend to contain glutamine-rich
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regions, transcriptional mechanisms should expect to see effects from the expanded quantities of
polyglutamine via mutant huntingtin. Researchers have seen the effects of mutant huntingtin on
transcriptional regulators, like CREB-binding proteins and cAMP response element-binding
proteins (Jimenez-Sanchez et al, 2017). Gene expression dysregulation has been observed as a
result of mutant huntingtin. In one study, researchers discovered the presence of mutant
huntingtin in several RNA structures that influence genetic expression posttranscriptionally, like
P bodies, stress granules, and dendritic RNA granules (Savas et al, 2010). It suggested that each
of these toxic effects by mutant huntingtin possibly play a role in accelerating the rate of
neurodegeneration, thus culminating in the prognosis of Huntington's disease.
Current Therapeutic Strategies
Researchers cannot agree, like with many neurodegenerative diseases, exactly how the
aforementioned mutation accelerates neuronal atrophy; however, evidence suggests that targeting
the overexpression of huntingtin could halt the disease progression. Current trials to repair the
mutation utilize antisense oligonucleotides [ASOs] and RNAi have yielded encouraging results
in clinical trials, but these experimental techniques are subject to faults.
Antisense oligonucleotides [ASOs] are small, synthetically engineered nucleic acids that
utilize Watson-Crick base pairing to bind to RNA sequences within the genome. This binding
can result in gene silencing or RNA modification. Gene silencing by ASOs can occur either
through degradative mechanisms in which an artificially manufactured endonuclease cleaves the
target RNA or non-degradative mechanisms in which where binding of the ASO sterically
obstructs subsequent translation and replication. Chemically, ASOs function through the
degradative mechanism, where an RNaseH molecule is bound with an oligonucleotide–RNA
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heteroduplex. Once bound, RNA that is bound to DNA in a heteroduplex will be cleaved by the
RNaseH, thus freeing the DNA. Any remaining ASO will essentially catalyze the degradation of
the subsequent RNA products, effectively silencing the genetic expression. When adapted for
individuals with Huntington’s disease, researchers hoped that this technology could be adapted to
target HTT, the gene responsible for the disease development. In one study, researchers found
promising results that suggested that silencing the overexpression of HTT through the use of
ASOs could successfully slow disease progression in transgenic mice. However, they did note
that ASOs would only temporarily silence the expression of HTT, and recipients would require
continued intermittent treatment to counteract the return of the neurodegenerative symptoms and
possible toxic effects (Southwell et al. 2012).
Another promising genetic therapy option utilized against Huntington’s is RNA
interference (RNAi), which Thermo Fisher (2019) defines as a phenomenon where small RNAs
bind to messenger RNAs (mRNA) that encode for specific proteins in order to inhibit subsequent
protein translation. RNAi begins when double-stranded RNA (dsRNA) is introduced into the
cell, whether that be by natural or artificial means. When the cells recognize the dsRNA, they
signal for an immune response to destroy this potentially harmful foreign body, which results in
dsRNA cut into smaller pieces (siRNA). These smaller pieces can bind with other cellular
components in the cell, thus creating new single-stranded RNA (ssRNA). These new ssRNAs
can then bind to target mRNA and inhibit the production of proteins encoded by those mRNAs.
When adapted for individuals with Huntington’s, researchers hoped that they could engineer
siRNA to target the HTT mRNA encoding for huntingtin, which would decrease the expression
of that protein. In one study, researchers found that RNAi could successfully be manipulated to
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target the HTT gene encoding for huntingtin. However, they noted that this therapy frequently
did not succeed; in several cases, they observed several off-target effects and severe organ
toxicity resulting in fatality in experimental models (Aguiar et al. 2017).
Because the proposed genetic therapeutic strategies cannot be fully controlled and
frequently induce off-target mutations, researchers have begun to investigate a priori strategies in
the literature that appear promising in neurodegeneration.
Experimental Therapeutic Strategies
One alternative for neurodegenerative treatment presents itself in the form of the genomic
editing technique called CRISPR. CRISPR, an acronym for clustered regularly interspaced short
palindromic repeats, can be defined as a family of DNA sequences found in regions of the
prokaryotic genome. It can be altered to search, remove, and replace specific DNA sequences to
repair any unwanted mutations; it could then either remove the mutation or signal the body to
repair that specific segment.  The CRISPR-Cas9 system consists of two components: the Cas9
endonuclease that will ligate the target sequence and a single guide RNA (sgRNA) that guides
the Cas9 to the target site. Upon binding to the targeted site, Cas9 induces a double-strand break
in the DNA that employs the non-homologous end joining (NHEJ) repair method, which will
facilitate the introduction of random nucleotides into the target site that encourages frameshift
mutations, thus disrupting any subsequent gene expression. In the case of Huntington’s,
researchers suggest that this system could be delivered into the brain in vivo and disrupt the
continued production of the HTT gene. When Huntington’s was simulated in mouse models
expressing the HTT gene and its CAG trinucleotide repeats, researchers hypothesized that the
therapeutic strategy would target HTT production and halt disease progression. They found that
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there was a reduced formation of neurotoxic fragments, increased expected lifespan, and
improved subsequent motor dysfunction in the mouse models. They admit that this therapy will
not restore lost neurons, implying that this technology would be most beneficial on those early in
their diagnosis; however, the neuronal cells could be recovered via cell replacement therapy
(Ekman et al. 2019). This preliminary study indicates that this therapy could yield more benefits
than traditional methods of treatment when used in conjunction with cell replacement therapy.
Some researchers nonetheless criticize this method of treatment because of the varying
limitations associated with genomic editing.
Researchers have considered the possibility of treating the disease by repressing
huntingtin transcription by binding zinc-finger domains of the expanded CAG repeats. Zinc
finger proteins (ZFP) can be engineered to include a second domain that can activate [or repress]
a target gene’s promoter to regulate its transcription. This strategy would be able to target any
desired sequence, including CAG repeats, thus overcoming one of the restrictions inherent to
CRISPR-Cas9 that prevents it from recognizing CAG repeats. In one study, when these ZFPs
were modeled in neural stem cells (NSCs) differentiated from embryonic stem cells expressing
the CAG repeats. In the NSCs, the engineered zinc proteins successfully repressed the
transcription of the diseased HTT gene corresponding with the CAG repeats without affecting
the transcription of normal HTT (Zeitler et al. 2019). In a similar study modeled in mice,
different configurations of these zinc proteins were shown to repress transcription at different
levels of efficiency. Longer zinc constructs were more successful in repressing mutant mRNA
expression and protein levels. Analysis of the brains further indicated that the introduction of the
zinc proteins slowed the rates of cranial decay in mice in the later stages of the disease, implying
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that this therapeutic strategy successfully slowed neurodegenerative progression as well
(Garriga-Canut et al. 2012). However, one shortcoming of this technique is that researchers have
had difficulty reproducing the results of similar experiments, meaning that this technique is not
stable enough to progress into clinical trials.
One last alternative for neurodegenerative treatment concerns the role of oxidative stress
on neuronal degeneration. Free radicals, like reactive oxidative species (ROS) for example,
regulate several pathways within the brain. However, an abundance of free radicals produced as a
result of these pathways can overwhelm the antioxidant response and induce cranial oxidative
stress. Oxidative stress occurs in the body when there is an imbalance between free radicals and
antioxidants that detoxify these products. This imbalance can be further influenced by certain
environmental, genetic, and age-related factors. For example, glial cells, found primarily in the
brain and spinal cord, generate large amounts of ROS during the glial inflammatory response.
Increased production of these free radicals can inhibit the antioxidant system response, which is
regulated by glial cells as well. As a result, glial cell dysfunction by oxidative stress will result in
reduced antioxidant production, leading to increased neurotoxicity in the brain. Researchers have
suggested that the inhibition of free radical production could prevent the accumulation of
oxidative stress, thus preventing the progression of neurodegeneration. However, none of the
past suggestions that focus on oxidative stress prevention have developed into viable therapeutic
strategies. Current research has demonstrated several barriers are hindering oxidative stress
reduction therapy, such as substandard clinical models and lack of access to certain brain regions.
Some neurologists have suggested that this strategy could work if treatment was personalized to
each individual; for example, if an individual suffers from reduced glutathione function, a major
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producer of antioxidants, then this therapeutic strategy could target these enzymes to enhance
their production. However, there has been no practical application of this strategy to date.
Researchers nonetheless are certain that personalized approaches when targeting oxidative stress
could lead to improved clinical outcomes (Neal and Richardson, 2018).
Ethics Concerning Neurodegenerative Detection and Treatment
Current efforts to detect and treat neurodegenerative disease, like the aforementioned
therapeutic strategies, are designed to identify and repair the responsible pathologies by genetic
alteration. Genetic therapy has been shown to correct genetic mutations at their source, often
without any serious side effects to the recipient. However, several groups have opposed the use
of genetic testing and editing for ethical reasons. Discussions concerning the use of these
technologies generally focus on the ethical, legal, and social consequences in humans. The
scientific and bioethical communities have observed debates concerning all facets of the future
of neurodegenerative identification and treatment for decades. Yet, they are no closer to a
consensus than they were when the technology was first introduced.
In the case of genetic testing, there have been discussions concerning the ethics of
predictive testing for Huntington’s disease. Predictive testing produces three different types of
ethical dilemmas: test accuracy and reliability, misuse of test information, and effect of test
information on affected individuals. The information from the predictive testing will be used by
those tested to make important decisions about their futures, and it is, therefore, essential to
know if the tests can be completely trusted. What are the possibilities that the results could lead
to false-positive results? Even with the advances in technology in this decade, there cannot be a
guarantee that these predictions will not be prone to occasional error. This ethical dilemma could
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further influence social dynamics since the results will be of interest to those close to the
individual tested. Prospective employers, marriage partners, and family members may demand to
be privy to the results, as they will often want to know whether this person will be around for the
long term. What if the afflicted individual does not wish to disclose this information? Does their
child not have the right to know that they may be a carrier for this disease as well? The most
important ethical consideration for predictive testing concerns the effect of the results on the
individual. Informing the individual of their disease could lead to increased rates of risky
behaviors like depression, recklessness, and suicide. The conflict between honesty and the
pledge to do no harm has always presented a clinical dilemma to healthcare providers when no
treatment is available. Providers tend to favor honesty when considering requests from patients
for information; the sooner they come to terms with their disease, then the sooner they can start
treating any symptoms (Coustasse et al 2009). However, consider a hypothetical case where a
provider tested an individual for several disorders as part of a theoretical standard annual exam.
He discovered and then informed the individual that he was a carrier for Huntington’s.
Unbeknownst to the individual, he would never exhibit symptoms and live a long life. Yet, after
finding out about his condition he decided to take his own life instead of risk the possibility of
developing the disease. Is the provider ethically bound to disclose to his patient the findings of
the exam, if they did not specifically request to know? There is currently no technique that would
allow researchers to predict how individuals will react psychologically to their predictive testing
results. Thus, it is of the utmost importance to researchers to establish and refine a code of ethics
concerning predictive testing.
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In the case of genetic editing, there have been discussions concerning the application of
these strategies in humans. Specifically concerning the CRISPR-Cas9 system, all therapeutic
utilization of this technology was studied in somatic cells before 2015. Genetic editing in
somatic cells generally does not require much ethical assessment because of the low risk/high
benefit balance. It is when this technology is applied to germline cells that we begin to consider
the multitude of risks associated with this application. The utilization of CRISPR-Cas9 in the
germline risks the manifestation of off-target effects in both current and future generations
(Ayanoğlu et al. 2020). Some argue that these studies should continue only in somatic cells,
where the risk/benefit balance can be established, as there is a high risk of off-target effects
developing even with controlled application. Conversely, some believe that new developments
by CRISPR-Cas9 could prevent off-target effects and that it should be further discussed (Yumlu
et al. 2019). Further issues have arisen concerning the application of this technology, like equal
access in terms of cost and social status; what kind of genetic flaws will this technology be used
for; and informed consent for those undergoing genetic therapy by this technology (Ayanoğlu et
al. 2020).
Despite being thoroughly debated for decades, the scientific community cannot agree on
the ethics of predictive testing on humans for neurodegenerative disease. As with ethics and
philosophy, there is never a clear answer on the correct course of action. Researchers, healthcare
providers, and at-risk individuals should consider all options regarding testing in order to avoid
any ethical or social complications.
Implications for Future Work
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A thorough investigation into the aforementioned experimental therapeutic strategies will
be of high relevance for the biomedical community. Currently, all these experimental methods
exist only theoretically because of the ethical and functional limitations placed upon these
techniques. For these techniques to progress to clinical trials, they would need to show safe,
stable, reproducible results in a lab setting. An analysis of the effects that these strategies incur in
vivo regarding mutant huntingtin expression, disease development and progression, and other
important pathological ramifications hold immense value, especially for the future of
neurodegenerative treatment. Even experiments with undesired results will be beneficial
nonetheless since little is known about the practical application of such strategies. Furthermore,
the current and experimental strategies will be subject to extensive ethical debate to determine
their applicability in future clinical trials.
Conclusion
Huntington's disease is a progressive disease that devastates at-risk individuals and those
closest to them. Over the last decade, there has been a rapid advancement in our understanding of
the pathogenesis of Huntington’s development and presentation. Currently, there are few
treatments available that seek to prevent the progression of the disease; furthermore, several
existing therapeutic strategies suggested by researchers have failed the clinical stage. There is a
desperate need for the development of novel therapeutic strategies capable of targeting the
mutant HTT gene responsible for inducing neurodegeneration. With researchers now considering
new genetic therapy strategies that show a priori promise, there is a real possibility that one day
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